Patients with carcinoid tumors frequently could benefit from the pharmacologic treatment of depression and anxiety. However, many prescribers avoid serotonergic medications due to the theoretical risk of exacerbating carcinoid syndrome. METH-ODS: The authors conducted a retrospective chart review of patients with carcinoid tumors and elevated serotonin levels (as measured by 24-hour urine 5-hydroxyindoleacetic acid [5-HIAA]) at Dana-Farber/Brigham and Women's Cancer Center who initiated treatment with serotonergic antidepressants after a carcinoid diagnosis from 2003 to 2016. Each medication regimen was categorized based on the presence of adverse interactions as defined by clinical worsening of symptoms of carcinoid syndrome in the absence of progressive disease that temporally correlated with a serotonergic medication trial. RESULTS: A total of 73 serotonergic regimens received by 52 patients were included in the primary analysis. Among these medication trials, 8.2% of the regimens (6 regimens) were categorized as being associated with a likely adverse interaction, 61.6% of the regimens (45 regimens) were categorized as having no adverse reaction, 9.6% of the regimens (7 regimens) were categorized as an unlikely adverse reaction, and 20.6% of the regimens (15 regimens) were categorized as unknown. It is interesting to note that none of the 73 trials resulted in a carcinoid crisis requiring emergency care or hospitalization. Only 3 patients discontinued serotonergic medications due to worsening carcinoid syndrome. CONCLUSIONS: Serotonergic medications appear to be a safe option for the treatment of depressive and anxiety symptoms in the majority of patients with neuroendocrine tumors and carcinoid syndrome. In the current study, <10% of patients developed a combination of flushing, diarrhea, and bloating after the initiation of serotonergic medications. Clinicians can begin with low doses, monitor these symptoms, and reduce the dose or discontinue the medication if necessary. Cancer 2017;123:2735-42.
INTRODUCTION
Carcinoid tumors are neuroendocrine malignancies derived from cells with the ability to secrete serotonin. Approximately 10% to 50% of patients with carcinoid tumors may develop carcinoid syndrome, which is characterized by flushing; diarrhea; abdominal cramping; and occasionally wheezing, tricuspid valve dysfunction, and pellagra. Carcinoid syndrome is believed to result from tumoral secretion of a variety of biologically active compounds, including serotonin, into the systemic circulation. 1 Metabolites have distinct causal roles in particular carcinoid symptoms. For example, bradykinin and serotonin have been implicated in bronchospasm, and tachykinins and histamine in flushing. 1 It is interesting to note that serotonin is believed to play a major role in causing diarrhea. Urinary excretion of 5-hydroxyindoleacetic acid (5-HIAA), the primary end product of serotonin metabolism, is commonly used as a diagnostic test for carcinoid syndrome, and has a sensitivity and specificity of >90% in this setting. 2, 3 The incidence of serotonin secretion (and associated carcinoid syndrome) varies by primary tumor site. Approximately 75% to 80% of patients with carcinoid syndrome have tumors arising in the midgut (distal small intestine and proximal colon); carcinoid syndrome is less often associated with bronchial or rectal (hindgut) carcinoid tumors. 4 Rates of carcinoid syndrome also are reported to be higher among patients with more extensive disease, because the presence of metastases, particularly in the liver, increases the likelihood that serotonin and other biologically active compounds will reach the systemic circulation. 5 Among patients with carcinoid syndrome, >90% have metastatic disease; in rare cases, primary tumors (such as ovarian carcinoids) may secrete hormones directly into the systemic circulation. 4 Several prior studies have examined the incidence of psychiatric disorders, including depression, in patients with carcinoid tumors. Theoretically, there is an increased risk of depression and other serotonin-related cognitive effects because serotonin produced by tumors may decrease the overall tryptophan pool, which is the essential substrate for producing serotonin in the central nervous system. The actual frequency of depression was noted to be as high as 50% in older studies from the 1970s and 1980s. 6, 7 However, more recent work has demonstrated lower rates of depression and characteristics of neuropsychological comorbidities. A relatively large survey-based study by Soliday et al (186 patients) found that 3.8% of their surveyed cohort demonstrated clinical depression, with 18.3% considered to be borderline or at risk. 8 It is interesting to note that these rates are somewhat lower than those demonstrated in recent high-quality meta-analyses of mixed cancer populations (which approximate 15% for major depression and 20% for minor depression). Additional literature has suggested that quality of life in patients with carcinoid tumors is lower compared with in healthy adults, but that levels of anxiety and depression are relatively low, with a tendency for anxiety to decrease and depression to increase as time elapses. 9, 10 Several studies have investigated neuropsychological features other than depression in patients with carcinoid tumors. In another study by Russo et al, approximately 75% of patients with carcinoid tumors fulfilled diagnostic criteria for an impulse control disorder (especially irritability with verbal aggression). Furthermore, patients with carcinoid syndrome may exhibit impaired verbal memory and delayed recall and visual-perceptual function. 11, 12 Similar studies have reported that patients with carcinoid syndrome demonstrate worse scores in all cognitive domains, including initiation, processing speed, cognitive efficiency, visual memory, and delayed verbal recall, compared with matched controls, 13 although sexual desire and function (also believed to be related to serotonin levels) do not appear to be different from what is noted in control populations. 14 When patients with carcinoid tumors and elevated 5-HIAA require treatment for depression and irritability, it is common to consider selective serotonin reuptake inhibitors (SSRIs). However, to our knowledge, it is unclear whether these medications are safe in this cohort of patients. Because SSRIs increase the availability of serotonin at the synapse and are not neuro-specific, with up to 90% of serotonin stores located within the gastrointestinal tract, they theoretically may exacerbate the systemic symptoms of carcinoid syndrome. The timing of this risk is likely when serotonin levels peak after the initiation of serotonergic medications. Chronic SSRI use has been associated with depressed serotonin levels, which together suggest that the risk of carcinoid syndrome exacerbation may be greater initially, with a decreasing likelihood once the patient has received treatment with serotonergic medications for an extended period of time. 15 Furthermore, symptoms of carcinoid syndrome (especially diarrhea, flushing, and autonomic instability) overlap with those of serotonin syndrome, which is caused by serotonin toxicity. This suggests that SSRI-induced exacerbation of the symptoms of carcinoid syndrome could be due to an excess of serotonin brought on by the serotonergic medication. However, to the best of our knowledge, the actual risk of serotonergic medications exacerbating carcinoid syndrome remains unclear.
There are case reports of sertraline, fluoxetine, and citalopram unmasking carcinoid syndrome in patients with an underlying carcinoid tumor who were not receiving octreotide. [16] [17] [18] In these reports, patients developed worsening diarrhea and subsequent weight loss and/or dehydration, with no additional symptoms reported to be exacerbated by serotonergic medications. Conversely, a case series of 5 patients with carcinoid tumors who received SSRIs after their diagnosis, including 2 patients who were receiving octreotide, suggested that treatment improved mood without causing or exacerbating the carcinoid syndrome. 19 More systematic research is necessary to determine the specific effect of serotonergic medications in patients with carcinoid syndrome, and to examine factors that differentiate patients who are susceptible to worsening carcinoid syndrome while receiving this class of medications. Patients with metastatic disease represent a high-risk cohort, constituting the vast majority of individuals with carcinoid syndrome. In addition, because carcinoid syndrome is directly related to elevated levels of serotonin, and elevated urinary 5-HIAA is a sensitive and specific indicator of elevated serotonin levels, the presence of elevated urinary 5-HIAA can be used as a tool to specifically identify a cohort of patients with carcinoid syndrome who may be at risk of the exacerbation of serotonergic medication-induced carcinoid symptoms. The goal of the current study was to systematically characterize the tolerability of serotonergic medications in a cohort of patients with metastatic carcinoid tumors and Original Article elevated serotonin levels as assessed by 24-hour urine 5-HIAA excretion.
MATERIALS AND METHODS
The current study was a retrospective chart review study of patients with metastatic neuroendocrine tumors (NETs) who were evaluated at Dana-Farber Cancer Institute from June 3, 2003 through March 1, 2016. Patients provided informed consent for enrollment into the NET database at the time of their initial clinic visit after a full explanation of the purpose and nature of all procedures used. Consent rates for the study exceeded 95%. Among 567 patients in the comprehensive Dana-Farber Cancer Institute NET database, 275 patients were identified as having metastatic disease and had regular follow-up (2 visits). Patients who received only a 1-time second opinion consultation were excluded due to the high probability of incomplete data regarding medication use. The patients in this remaining cohort then were screened for any use of serotonergic medications at any point in their treatment history. The medical records for these patients were searched for key terms ("depression," "anxiety," "SSRI," and generic and trade names for each serotonergic medication). Serotonergic medication use was confirmed via clinical notes and medication lists. A total of 190 patients were found to have any serotonergic medication use. We further narrowed this cohort to 70 patients who had 1 documented elevated 24-hour urine 5-HIAA level. This was done to identify an at-risk cohort of patients with carcinoid tumors who may not tolerate serotonergic medications. Patients who already were receiving serotonergic antidepressants before the diagnosis of NET were excluded (18 patients) (Fig. 1) .
Basic demographic information and clinical variables were abstracted from the medical record, including age, date of diagnosis, and location of the primary tumor. The primary outcome was the presence of an adverse effect of serotonergic medication on carcinoid syndrome, which was assessed based on a categorization scheme outlined in Table 1 . This categorization took into account changes in carcinoid symptoms, reason for medication discontinuation, and the presence of progressive disease as defined by radiographic progression of disease while undergoing treatment with serotonergic medication. The information was abstracted from the medical record via clinical notes and medication prescription history.
The presence of adverse interactions was broadly categorized as 1) no apparent adverse interaction, 2) unlikely adverse interaction, 3) likely adverse interaction, and 4) unknown. Patients were categorized as having no apparent adverse interaction (category 1) if they had no increase in carcinoid syndrome symptoms (diarrhea, flushing, and/or autonomic instability) within 3 months of the initiation of serotonergic medications as documented by clinical notes. Patients were categorized as having an unlikely adverse interaction (category 2) if they had an increase in carcinoid symptoms with documented radiographic progression of disease (making the serotonergic medication an 
Statistical Analysis
Statistical analysis was performed using descriptive statistics, including average duration of medication trials, percentages of each adverse interaction category, and the mean number of trials per patient.
RESULTS
A total of 52 patients and 73 serotonergic antidepressant medication trials (comprising 8 distinct medications) were included in the primary analysis. Among this group of patients, 48 patients (92.3%) had carcinoid symptoms (flushing and/or diarrhea as documented in clinical notes) before the initiation of a serotonergic medication. The average number of serotonergic medication trials per patient was 1.40. There were 37 men and 15 women (71.2% and 28.9%, respectively), and all patients had metastatic disease. The most common medication prescribed was citalopram, followed by trazodone and sertraline (Table 2) . Approximately 25% of patients (13 patients) were referred to the cancer psychiatry service. Among the 73 medication trials, 45 (61.6%) were categorized as having no apparent adverse interaction, 7 (9.6%) were categorized as having an unlikely adverse interaction, 6 (8.2%) were categorized as having a likely adverse interaction, and 15 (20.6%) had an unknown status (Table 2) . It is interesting to note that although fluvoxamine is an SSRI and therefore was included as a search term for data collection, there were no fluvoxamine trials in the current study cohort. Among the medication trials categorized as having no apparent adverse interaction, 11 trials (24.4%) later were discontinued due to symptoms unrelated to carcinoid syndrome (eg, fatigue, nausea, and sexual side effects), and 2 (4.4%) were discontinued due to the patient no longer having depressive symptoms without documentation of adverse interactions. It is interesting to note that 2 patients had overlapping serotonergic medication trials (both were receiving citalopram and trazodone simultaneously), neither of whom were categorized as having a likely adverse interaction. We did not observe any cases in which a serotonergic medication unmasked carcinoid syndrome. The mean and median duration across all trials was 576.0 days (standard deviation, 982.1 days) and 144 days (IQR 30-603.5 days), respectively. A total of 28 trials (38.4%) were 6 months in duration ( Table 2 ). There were no acute carcinoid crises requiring emergency care or hospitalization after the initiation of serotonergic medication, even among patients who were categorized as having a likely adverse interaction. Among the 6 patients who developed increased carcinoid symptoms after the initiation of serotonergic medication, the most common symptoms were flushing and diarrhea. Flushing was described in 2 of 6 patients, and diarrhea was described in 5 of 6 patients (Table 3 ). Three patients who reported an increase in diarrhea (patients 1, 2, and 3 in Table 3 ) discontinued serotonergic medications due to these symptoms, and the other 3 patients continued medications for 9 months, 25 months, and 8 years, respectively.
A total of 18 patients (5 men and 13 women) were excluded from the primary analysis due to having been receiving serotonergic medications before the diagnosis of their carcinoid tumor. Among these 18 patients, 5 had treatment initiated with additional serotonergic medication trials after diagnosis. The categorization of these medication trials is as follows: 3 trials were categorized as having no apparent adverse interaction, 1 trial was categorized as having an unlikely adverse interaction, and 1 trial was categorized as having a likely adverse interaction. The patient whose regimen was categorized as having a likely adverse interaction developed flushing, nausea, vomiting, and diarrhea 2 days after the initiation of treatment with 37.5 mg twice daily of venlafaxine. Venlafaxine was discontinued and the symptoms resolved. It is interesting to note that noradrenergic reuptake inhibition does not take effect at venlafaxine doses of <150 mg/day, and therefore was unlikely to be a causal component in this patient's adverse interaction. It also is worth noting that among these 18 patients who were excluded from the current analysis, the mean and median duration of treatment with serotonergic medications were 1613 days (standard deviation, 1100 days) and 802 days (interquartile range, 1477 days), respectively. Approximately 54.3% of the medication trials were 6 months in duration. There were no acute carcinoid crises reported among these patients.
DISCUSSION
In this cohort of patients who were initiated on serotonergic medications after a diagnosis of carcinoid tumor, only a small minority (6 of 73 patients; 8.2%) had worsened carcinoid symptoms within 3 months of the initiation of treatment with serotonergic medications. It is interesting to note that 3 of these patients continued taking the serotonergic medications for 9 months. A majority of the medication trials (45 of 73 trials; 61.6%) were categorized as no apparent adverse interaction (category 1). The overall median duration of treatment with serotonergic medication was 4.8 months, with 38.4% of the medication trials lasting 6 months. There were no acute carcinoid Initiated citalopram (10 mg every d) for depressive symptoms. Interesting to note that the patient had exhibited worsening diarrhea within the 6 wk prior to the initiation of citalopram. Three d after initiation, the patient was hospitalized for continued nausea, vomiting, and diarrhea. The patient continued to take citalopram for 2 y and 1 mo, after which time the patient was cross-tapered to sertraline due to increased depressed mood and fatigue. crises reported among patients in this cohort or among patients who were receiving serotonergic medications before diagnosis. To our knowledge, the current study is one of the largest studies to date to examine adverse interactions of serotonergic antidepressant medications in patients with carcinoid syndrome. To identify the group of patients theoretically at highest risk of exacerbated carcinoid symptoms with serotonergic medications, we restricted our study cohort to patients with metastatic carcinoid tumors and elevated 24-hour urine 5-HIAA levels. Despite this, the data from the current study suggest that the percentage of patients who experience worsening of carcinoid syndrome after the initiation of a serotonergic antidepressant is quite small. This may suggest that the physiology of carcinoid syndrome is more complex than the accepted framework suggests, and results from interactions among numerous biologically active compounds including but not limited to serotonin. It is interesting to note that the 6 patients (8.1%) who experienced a likely adverse interaction had all received SSRIs as opposed to trazodone. This may reflect the fact that trazodone at low doses only weakly inhibits serotonin reuptake, primarily acting instead as a postsynaptic serotonin receptor antagonist, and would not be expected to increase blood serotonin levels.
Even among patients who did experience worsening symptoms after initiation of the antidepressant, many continued to take the medication for months to years thereafter. This could be because their symptoms were not believed to be due to the antidepressant, or that their disease was beginning to progress and symptoms of carcinoid were manageable with other medications or interventions. Among the patients who were excluded from the primary analysis due to having been receiving a serotonergic medication before diagnosis, the mean and median durations of treatment were quite long, and there were no reported carcinoid crises. It is interesting to note that the primary analysis cohort was largely skewed toward men (37 men vs 13 women). This likely is due to the fact that a greater percentage of women were receiving serotonergic medications before their carcinoid diagnosis (5 men vs 13 women), and therefore were excluded from the primary analysis.
Objective serotonin-related biochemical measures, specifically 24-hour urinary 5-HIAA levels before and after the initiation of serotonergic medications, were not used to characterize medication tolerability for several reasons. Practically, only 12 of the 73 medication trials (16.4%) in the current study cohort had 5-HIAA levels that were conducted within 3 months of the initiation of the serotonergic medication. Even for those regimens with available pretreatment and posttreatment 5-HIAA levels, it is unclear that the timing of these levels would have appropriately captured the acute effect of the SSRI. Specifically, within the first few days to a week after initial serotonin reuptake blockade, serotonin and 5-HIAA concentrations increase. However, by the 2-week mark, the presynaptic somatodendritic serotonin type 1A (5-HT1A) autoreceptor responds by reducing the firing rate of the presynaptic serotonin neuron, resulting in a rapid drop in 5-HIAA concentrations. 20 The chronic administration of SSRIs is associated with decreased levels of extracellular 5-HIAA, 15 which complicates the interpretation of 5-HIAA levels drawn a few weeks or months after initiation of the medication.
We did not observe any instances of serious carcinoid syndrome symptoms, as has been described in case reports of carcinoid syndrome exacerbated by use of serotonergic medications. The current study data are more consistent with the previously described case series published by Williams et al in 2005. 19 Among the 5 patients with carcinoid tumor (only 1 of whom had documented carcinoid syndrome) who were treated with serotonergic antidepressants, none experienced exacerbation of carcinoid symptoms. 19 To the best of our knowledge, outside of case reports and case series, the amount of data regarding the use of serotonergic antidepressants in patients with carcinoid tumors are limited. A retrospective review from Memorial Sloan Kettering Cancer Center has described antidepressant use in a cohort of 92 patients (16 of whom had carcinoid syndrome); among patients with carcinoid syndrome who discontinued the medication, carcinoid syndrome was never reported as the reason for discontinuation. 21 The current study is not without its limitations. It was a retrospective analysis, and the results should be interpreted within the standard limitations of retrospective studies. For example, there is a possibility of selection bias in that clinicians may have avoided prescribing serotonergic medications to patients whose carcinoid syndrome was considered to be unstable or life-threatening (eg, valvular heart disease or cardiovascular compromise). In addition, there was a significant amount of missing data in the form of undocumented symptoms, medication side effects, and medication adherence, thereby necessitating the categorization of 20% of regimens as unknown. We did not have consistent information regarding whether the SSRI improved mood or anxiety symptoms. Furthermore, we developed the adverse interaction categorization for this project in a way that we believed reasonably captured the effect of the serotonergic medication on carcinoid symptoms. However, it is not a categorization scheme that has been validated outside of the current analysis. Given the small number of patients in whom serotonergic medications appeared to cause an adverse interaction, we had insufficient power with which to analyze any potential demographic or clinical characteristics associated with the adverse interaction. Finally, despite being what to our knowledge is one of the largest cohort studies reporting serotonergic antidepressant tolerability among patients with carcinoid syndrome presented to date, the current study is still small enough that we may not have encountered an instance of SSRI-induced carcinoid crisis. Although potentially rare, this would be a serious adverse event that prescribers would need to be aware of. Further prospective, controlled trials, also accounting for nonpsychiatric serotonergic agents such as linezolid, triptans, and tramadol, are indicated to address these issues.
It often is theorized that serotonergic antidepressants should be avoided in patients with carcinoid syndrome, and the fear of carcinoid symptom exacerbation likely is bolstered by dramatic case reports of adverse reactions. However, it is unclear whether these medications should be avoided entirely in these patients, who may have significant depressive symptoms. This is not to say that use in these patients is entirely without risk; in the current study cohort, 6 patients did experience increased carcinoid symptoms. However, none of these patients experienced a carcinoid crisis, and other options for carcinoid symptom control (such as titration of octreotide) may be sufficient to mediate carcinoid symptoms while still adequately treating depressive symptoms. Furthermore, among the patients who developed increased carcinoid symptoms, the nature of the symptoms was a combination of flushing, diarrhea, and bloating. These symptoms can be easily assessed by clinicians, and the serotonergic medication can be dose-adjusted or discontinued if necessary. We have observed that patients with carcinoid syndrome who require medications for the management of mood or anxiety occasionally are unsuccessfully tried on several alternative, nonserotonergic medications before finally having treatment with an SSRI initiated, with rapid clinical benefit. Although the risk of carcinoid exacerbation is present, the data from the current study suggest that serotonergic medications appear to be safe options for the treatment of symptoms of depression and anxiety in the majority of patients with NETs and carcinoid syndrome. Thus, clinicians treating these patients can consider serotonergic medications as a first-line treatment for symptoms of depression and/or anxiety, with close monitoring of symptoms and discontinuation or dose reduction as necessary.
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